These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 36624188)

  • 21. ALK-Rearranged Epithelioid Mesenchymal Neoplasm: Expanding the Spectrum of Tyrosine Kinase-Altered Mesenchymal Tumors.
    Gestrich CK; Davis JL; Biederman L; John I; Alaggio R; Giovannoni I; Arnold MA; Shenoy A; Tchakarov A; Al-Ibraheemi A
    Mod Pathol; 2023 Dec; 36(12):100334. PubMed ID: 37726067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reclassification of a spindle cell sarcoma after identification of a TFG-ROS1 fusion: A case demonstrating the clinical benefit of next-generation sequencing in sarcoma.
    Lim JJ; Chen EY; Schaub SK; Wagner MJ
    Mol Genet Genomic Med; 2024 Apr; 12(4):e2423. PubMed ID: 38622850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ALK Is a Specific Diagnostic Marker for Inflammatory Myofibroblastic Tumor of the Uterus.
    Mohammad N; Haimes JD; Mishkin S; Kudlow BA; Leong MY; Chew SH; Koay E; Whitehouse A; Cope N; Ali RH; Köbel M; Stewart CJR; McCluggage WG; Lee CH
    Am J Surg Pathol; 2018 Oct; 42(10):1353-1359. PubMed ID: 30015720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inflammatory myofibroblastic tumor and low-grade myofibroblastic sarcoma: a comparative study of clinicopathologic features and further observations on the immunohistochemical profile of myofibroblasts.
    Qiu X; Montgomery E; Sun B
    Hum Pathol; 2008 Jun; 39(6):846-56. PubMed ID: 18400254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathologic and Genomic Characterization of Inflammatory Myofibroblastic Tumors of the Head and Neck: Highlighting a Novel Fusion and Potential Diagnostic Pitfall.
    Kerr DA; Thompson LDR; Tafe LJ; Jo VY; Neyaz A; Divakar P; Paydarfar JA; Pastel DA; Shirai K; John I; Seethala RR; Salgado CM; Deshpande V; Bridge JA; Kashofer K; Brčić I; Linos K
    Am J Surg Pathol; 2021 Dec; 45(12):1707-1719. PubMed ID: 34001695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
    Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
    J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PD-L1 expression and CD8+ tumor-infiltrating lymphocytes are associated with ALK rearrangement and clinicopathological features in inflammatory myofibroblastic tumors.
    Cha YJ; Shim HS
    Oncotarget; 2017 Oct; 8(52):89465-89474. PubMed ID: 29163763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases.
    Coffin CM; Hornick JL; Fletcher CD
    Am J Surg Pathol; 2007 Apr; 31(4):509-20. PubMed ID: 17414097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
    Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
    Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ALK-rearranged Tumors Are Highly Enriched in the STUMP Subcategory of Uterine Tumors.
    Devereaux KA; Kunder CA; Longacre TA
    Am J Surg Pathol; 2019 Jan; 43(1):64-74. PubMed ID: 29794871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ALK Immunoexpression is Specific for Inflammatory Myofibroblastic Tumor Among Vulvovaginal Mesenchymal Neoplasms.
    Bowman CJ; Medeiros F; Fadare O; Sangoi AR; Horvai AE; Devine WP; McCluggage WG; Rabban JT
    Int J Gynecol Pathol; 2023 Jan; 42(1):1-10. PubMed ID: 35180768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinicopathological features of inflammatory myofibroblastic tumor].
    Zhu Y; Ding Y; Song GX; Li X; Ding R; Fan QH; Gong QX
    Zhonghua Bing Li Xue Za Zhi; 2021 Mar; 50(3):194-200. PubMed ID: 33677881
    [No Abstract]   [Full Text] [Related]  

  • 33. Gene rearrangements in consecutive series of pediatric inflammatory myofibroblastic tumors.
    Preobrazhenskaya EV; Iyevleva AG; Suleymanova AM; Tiurin VI; Mitiushkina NV; Bizin IV; Ivanstov AO; Gorustovich OA; Shelekhova KV; Kachanov DY; Varfolomeeva SR; Roschin VY; Kazakova AN; Litvinov DV; Shamanskaya TV; Savelov NA; Suspitsin EN; Imyanitov EN
    Pediatr Blood Cancer; 2020 May; 67(5):e28220. PubMed ID: 32064735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.
    Pietrantonio F; Di Nicolantonio F; Schrock AB; Lee J; Tejpar S; Sartore-Bianchi A; Hechtman JF; Christiansen J; Novara L; Tebbutt N; Fucà G; Antoniotti C; Kim ST; Murphy D; Berenato R; Morano F; Sun J; Min B; Stephens PJ; Chen M; Lazzari L; Miller VA; Shoemaker R; Amatu A; Milione M; Ross JS; Siena S; Bardelli A; Ali SM; Falcone A; de Braud F; Cremolini C
    J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29370427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inflammatory myofibroblastic tumors of the urinary tract: a clinicopathologic study of 46 cases, including a malignant example inflammatory fibrosarcoma and a subset associated with high-grade urothelial carcinoma.
    Montgomery EA; Shuster DD; Burkart AL; Esteban JM; Sgrignoli A; Elwood L; Vaughn DJ; Griffin CA; Epstein JI
    Am J Surg Pathol; 2006 Dec; 30(12):1502-12. PubMed ID: 17122505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance Mechanisms to Targeted Therapies in
    McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
    Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
    [No Abstract]   [Full Text] [Related]  

  • 37. Uterine Inflammatory Myofibroblastic Tumor Showing an Atypical ALK Signal Pattern by FISH and DES-ALK Fusion by RNA Sequencing: A Case Report.
    Zarei S; Abdul-Karim FW; Chase DM; Astbury C; Policarpio-Nicolas MLC
    Int J Gynecol Pathol; 2020 Mar; 39(2):152-156. PubMed ID: 30741845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Uterine inflammatory myofibroblastic tumor.
    Karpathiou G; Devouassoux-Shisheboran M; Stolnicu S; Chauleur C; Péoc'h M
    Pathol Res Pract; 2023 Feb; 242():154335. PubMed ID: 36706588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inflammatory myofibroblastic tumor of the uterus - case report.
    Štiková Z; Ptáková N; Horáková M; Kosťun J; Ondič O
    Cesk Patol; 2019; 55(4):239-243. PubMed ID: 31842556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
    Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
    Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.